Premium
Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review
Author(s) -
Post Robert M,
Frye Mark A,
Denicoff Kirk D,
Leverich Gabriele S,
Dunn Robert T,
Osuch Elizabeth A,
Speer Andrew M,
Obrocea Gabriela,
Jajodia Kamal
Publication year - 2000
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1034/j.1399-5618.2000.020403.x
Subject(s) - lamotrigine , topiramate , carbamazepine , bipolar disorder , gabapentin , lithium (medication) , rapid cycling , bipolar ii disorder , psychiatry , medicine , mood , mood stabilizer , hypomania , psychology , mania , epilepsy , alternative medicine , pathology
Recent evidence suggests that lithium therapy (even as supplemented by antidepressants and neuroleptics) is inadequate for the majority of patients with bipolar illness, and particularly those with rapid cycling. Valproate and carbamazepine have emerged as adjuncts and alternatives, but they, too, often require additional approaches with lithium, thyroid hormones, and other putative mood stabilizers, including nimodipine (and related dihydropyridine calcium channel blockers), lamotrigine, gabapentin, topiramate, and the atypical neuroleptics. Evaluating how these agents and the unimodal antidepressants are optimally applied and sequenced in the treatment of bipolar illness with its multiple subtypes, patterns and comorbidities will require much future investigation and the development of new methodological clinical trial approaches.